Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

42.9%

3 terminated out of 7 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
P 2 (3)

Trial Status

Terminated3
Recruiting2
Active Not Recruiting1
Not Yet Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT05575440Terminated

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

NCT05591092TerminatedPrimary

Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

NCT03914300Phase 2Active Not Recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

NCT07545837Not ApplicableRecruitingPrimary

Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors

NCT07529080Not ApplicableNot Yet Recruiting

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

NCT06440850Phase 2RecruitingPrimary

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT03506048Phase 2Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Showing all 7 trials

Research Network

Activity Timeline